v3.25.2
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
segment
Segment Reporting Information [Line Items]            
Number of operating segments | segment         1 1
Number of reportable segments | segment         1 1
Revenues $ 10,003   $ 20,099   $ 18,723 $ 32,152
Costs and expenses:            
Total Manufacture and Supply Expenses 4,561   4,526   8,213 8,915
Total Research and Development Expenses 4,105   4,162   9,466 10,094
General & Administrative expenses:            
Total Selling, General and Administrative Expenses 12,705   11,356   31,777 22,045
Total costs and expenses 21,371   20,044   49,456 41,054
Loss from operations (11,368)   55   (30,733) (8,902)
Net loss before income taxes (13,548)   (2,745)   (36,478) (15,573)
Net loss (13,548) $ (22,930) (2,745) $ (12,828) (36,478) (15,573)
Comprehensive loss (13,548)   (2,745)   (36,478) (15,573)
Reportable Segment            
Segment Reporting Information [Line Items]            
Revenues 10,003   20,099   18,723 32,152
Costs and expenses:            
Total Manufacture and Supply Expenses 4,561   4,526   8,213 8,915
Total Research and Development Expenses 4,105   4,162   9,466 10,094
Selling expenses:            
Total Selling expenses 3,520   1,068   6,476 2,141
General & Administrative expenses:            
Total General and Administrative Expenses 9,185   10,288   25,301 19,904
Total Selling, General and Administrative Expenses 12,705   11,356   31,777 22,045
Total costs and expenses 21,371   20,044   49,456 41,054
Loss from operations (11,368)   55   (30,733) (8,902)
Other income/(expenses), net (2,180)   (2,800)   (5,745) (6,671)
Net loss before income taxes (13,548)   (2,745)   (36,478) (15,573)
Net loss (13,548)   (2,745)   (36,478) (15,573)
Comprehensive loss (13,548)   (2,745)   (36,478) (15,573)
Reportable Segment | Anaphylm project expenses            
Costs and expenses:            
Total Research and Development Expenses 1,204   1,700   3,692 4,847
Reportable Segment | AQST-108 project expenses            
Costs and expenses:            
Total Research and Development Expenses 190   0   385 789
Reportable Segment | Libervant project expenses            
Costs and expenses:            
Total Research and Development Expenses 0   0   0 17
Reportable Segment | Personnel costs            
Costs and expenses:            
Total Research and Development Expenses 2,218   2,039   4,350 3,743
Selling expenses:            
Total Selling expenses 608   254   1,302 1,186
General & Administrative expenses:            
Total General and Administrative Expenses 5,176   4,918   10,016 9,579
Reportable Segment | Other            
Costs and expenses:            
Total Research and Development Expenses 493   423   1,039 698
Selling expenses:            
Total Selling expenses 2,912   814   5,174 955
General & Administrative expenses:            
Total General and Administrative Expenses $ 4,009   $ 5,370   $ 15,285 $ 10,325